758684-29-6

Basic information

• Product Name: 3,4-Dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester
• Synonyms: 3,4-Dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester;Methyl 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate;Methyl 3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate;Methyl 2-(cyclohex-2-en-1-yl)-2H-oxazine-6-carboxylate;,4-Dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid Methyl ester
• CAS NO: 758684-29-6
• Molecular Formula: C₁₀H₁₁NO₃
• Molecular Weight: 193.2
• Mol File: 758684-29-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 73-74 °C
• Boiling Point: 337.7°C at 760 mmHg
• Flash Point: 158°C
• Appearance: /
• Density: 1.198g/cm³
• Vapor Pressure: 0.000103mmHg at 25°C
• Refractive Index: 1.539
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.60±0.20(Predicted)
• CAS DataBase Reference: 3,4-Dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester(758684-29-6)
• EPA Substance Registry System: 3,4-Dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester(758684-29-6)

Safety Data

• Hazardous Substances Data: 758684-29-6(Hazardous Substances Data)

Usage

General Description

3,4-Dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester, also known as DOM, is a chemical compound with the molecular formula C10H11NO3. It is a derivative of the psychoactive drug MDA and belongs to the family of benzoxazines. DOM is a synthetic hallucinogen and has been classified as a Schedule I controlled substance in the United States. It is known for its potent hallucinogenic effects, similar to those of LSD, and is often used recreationally for its mind-altering properties. However, its use poses significant health risks, including psychotic reactions, seizures, and even death. Consequently, it is illegal to manufacture, possess, or distribute DOM in many countries.

InChI:InChI=1/C10H11NO3/c1-13-10(12)7-2-3-9-8(6-7)11-4-5-14-9/h2-3,6,11H,4-5H2,1H3

Upstream product

• 873852-15-4 methyl 4-(2-ethoxy-2-oxoethoxy)-3-nitrobenzoate 
• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 536-25-4 methyl 3-amino-4-hydroxybenzoate 
• 106-93-4 ethylene dibromide 
• 604756-32-3 methyl 3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate 
• 83785-14-2 methyl 4-(2-methoxy-2-oxo-ethoxy)-3-nitrobenzoate 
• 616-82-0 3-nitro-4-hydroxybenzoic acid 
• 99-42-3 methyl (4-hydroxy-3-nitro)benzoate 

Downstream Products

• 1313994-11-4 ethyl 3-(2-((9H-purin-6-ylthio)methyl)-5-chloro-4-oxoquinazolin-3(4H)-yl)-4-methoxybenzoate 
• 1309477-85-7 methyl 4-tosyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate 
• 946120-73-6 4-(5-chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester 

Relevant articles and documents

The discovery of potent small molecule activators of human STING

The adaptor protein STING plays a major role in innate immune sensing of cytosolic nucleic acids, by triggering a robust interferon response. Despite the importance of this protein as a potential therapeutic target for serious unmet medical conditions inc

COMPOUND HAVING 11 ?-HSD1 INHIBITORY ACTIVITY

The present invention provides compounds having excellent 11β-HSD1 inhibitory activity. A compound represented by the following formula (I): [wherein X1 represents an oxygen atom, or the formula -(CR11R12)p-, etc., Y1 represents a hydrogen atom, a hydroxyl group, etc., Z1 represents an oxygen atom or the formula -(NR14)-, R1 represents a hydrogen atom, a halogen atom, a cyano group, a C1-4 alkyl group, a C1-4 alkyl group substituted with 1 to 3 halogen atoms, a C1-4 alkoxy group, a C1-4 alkoxycarbonyl group, a carboxyl group, a carbamoyl group, or an amino group, and m represents an integer of 1 or 2, and R2 represents a hydrogen atom or a C1-4 alkyl group, and n represents an integer of 1 or 2].

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.